Alpha 2.0
Login Register
» Authors » Sigrid Machherndl-Spandl

Sigrid Machherndl-Spandl

Explore the profile of Sigrid Machherndl-Spandl including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 41
Citations 329
Followers 0
Related Specialties
Hematology
Oncology
Molecular Biology
Top 10 Co-Authors
Reinhard Stauder
Ansgar Weltermann
Michael Pfeilstocker
Peter Valent
Andreas Petzer
Veronika Buxhofer-Ausch
Wolfgang R Sperr
Heinz Sill
Richard Greil
Armin Zebisch
Published In
Am J Hematol
Cancers (Basel)
Wien Klin Wochenschr
Ophthalmologie
Cytotherapy
Affiliations
Soon will be listed here.
Recent Articles
1.
Donor C1 Group KIR-ligand inferiority is linked to increased mortality in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide
Nikoloudis A, Bauhofer A, Griessl L, Habermehl A, Groiss C, Binder M, et al.
Cytotherapy . 2025 Jan; PMID: 39755976
Background Aims: In HLA-identical hematopoietic stem cell transplantation (HSCT), HLA-C1 group killer cell immunoglobulin-like receptor (KIR) ligands have been linked to graft-versus-host disease, whereas C2 homozygosity was associated with increased...
2.
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen-Single-Center Analysis
Machherndl-Spandl S, Hannouf S, Nikoloudis A, Zach O, Strassl I, Kaynak E, et al.
Cancers (Basel) . 2024 Oct; 16(19). PMID: 39409879
(1) Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is the only treatment with the potential for cure in patients with myelofibrosis (MF). However, the risk of graft rejection, which is particularly...
3.
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, et al.
EJHaem . 2024 Jun; 5(3):494-504. PMID: 38895059
Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with...
4.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, et al.
Am J Hematol . 2024 Mar; 99(5):1008-1011. PMID: 38425185
Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.
5.
Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, et al.
Cytotherapy . 2024 Feb; 26(5):490-497. PMID: 38385908
Background Aims: Cyclosporin A (CsA) remains a major component of immunosuppressive regimens applied in allogeneic hematopoietic stem cell transplantation (HSCT). The impact of CsA trough levels during the first weeks...
6.
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience
Strassl I, Nikoloudis A, Machherndl-Spandl S, Buxhofer-Ausch V, Binder M, Wipplinger D, et al.
Cancers (Basel) . 2023 Dec; 15(24). PMID: 38136284
Background: Despite major treatment advances, multiple myeloma remains incurable. The outcome of patients who are refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies is poor, and improved treatment...
7.
Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis
Nikoloudis A, Neumann I, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, et al.
Vaccines (Basel) . 2023 Oct; 11(10). PMID: 37896938
(1) Background: mRNA COVID-19 vaccines are effective but show varied efficacy in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients. (2) Methods: A retrospective study on 167 HSCT...
8.
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
Bauer K, Machherndl-Spandl S, Kazianka L, Sadovnik I, Gultekin S, Suessner S, et al.
Leukemia . 2023 Sep; 37(11):2250-2260. PMID: 37673973
Myelodysplastic syndromes (MDS) are myeloid neoplasms presenting with dysplasia in the bone marrow (BM) and peripheral cytopenia. In most patients anemia develops. We screened for genes that are expressed abnormally...
9.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT
Pleyer L, Vaisband M, Drost M, Pfeilstocker M, Stauder R, Heibl S, et al.
Am J Hematol . 2023 Aug; 98(11):1685-1698. PMID: 37548390
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with...
10.
Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, et al.
Cells . 2023 Jul; 12(14). PMID: 37508496
In allogeneic hematopoietic stem cell transplantation (HSCT), Anti-T-Lymphocyte Globulin (ATLG) may be used for the prevention of severe graft-versus-host disease (GVHD). ATLG targets both the recipient's lymphocytes and those transferred...